CD4 and type 1 diabetes mellitus: We set out to assess the cell surface phenotype of IAR CD4+ T cells in peripheral blood mononuclear cells (PBMCs) collected prior to treatment from 11 alefacept- and 7 placebo-treated new-onset T1D patients enrolled in the T1DAL clinical trial (Table 1).